Cannabidiol Oil Ingested as Sublingual Drops or Within Gelatin Capsules Shows Similar Pharmacokinetic Profiles in Healthy Males.

IF 3.1 4区医学 Q2 PHARMACOLOGY & PHARMACY Cannabis and Cannabinoid Research Pub Date : 2024-10-01 Epub Date: 2023-09-22 DOI:10.1089/can.2023.0117

Drusus A Johnson, Mark P Funnell, Liam M Heaney, Thomas G Cable, Patrick C Wheeler, Stephen J Bailey, Tom Clifford, Lewis J James

{"title":"Cannabidiol Oil Ingested as Sublingual Drops or Within Gelatin Capsules Shows Similar Pharmacokinetic Profiles in Healthy Males.","authors":"Drusus A Johnson, Mark P Funnell, Liam M Heaney, Thomas G Cable, Patrick C Wheeler, Stephen J Bailey, Tom Clifford, Lewis J James","doi":"10.1089/can.2023.0117","DOIUrl":null,"url":null,"abstract":"Introduction: Cannabidiol (CBD) is a nonintoxicating phytocannabinoid used in clinical treatments and sold widely in consumer products. CBD products may be designed for sublingual or oral delivery, but it is unclear whether either is advantageous for CBD absorption. This study compared CBD pharmacokinetics after providing CBD oil as sublingual drops and within orally ingested gelatin capsules, at a dose relevant to consumer products. Materials and Methods: Eight males completed three conditions in a participant-blinded, randomized crossover design. Participants received the following combinations of placebo and CBD-containing (69 mg/mL) hemp oil in capsules and as sublingual drops: placebo capsules/placebo drops (Placebo), CBD capsules/placebo drops (CBD-Caps), and placebo capsules/CBD drops (CBD-Drops). Blood samples, blood pressure, and subjective scales were obtained/completed hourly for 6 h and at 24 h. Discussion: Plasma CBD concentrations were not different between CBD-Caps and CBD-Drops (interaction effect p=0.76). Peak CBD concentration (28.0±15.6 vs. 24.0±22.2 ng/mL), time of peak CBD concentration (4±1 vs. 4±2 h), and area under the concentration curve (45.3±20.3 vs. 41.8±23.3 ng/mL·6 h) were not different between conditions (p≥0.25). Cardiometabolic outcomes (plasma glucose/triacylglycerol, heart rate, blood pressure), liver function (plasma alanine aminotransferase/aspartate aminotransferase), kidney function (plasma creatinine), and subjective feelings/symptoms were not different between conditions (p≥0.07). Conclusions: Plasma CBD profiles were comparable between CBD-Caps and CBD-Drops, suggesting that there were not meaningful differences in routes of CBD absorption between conditions. This implies that CBD oil delivered sublingually is swallowed before oral mucosal CBD absorption occurs, which may have implications for research design, CBD product design, and consumer product choice.","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":"e1423-e1432"},"PeriodicalIF":3.1000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cannabis and Cannabinoid Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/can.2023.0117","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Cannabidiol (CBD) is a nonintoxicating phytocannabinoid used in clinical treatments and sold widely in consumer products. CBD products may be designed for sublingual or oral delivery, but it is unclear whether either is advantageous for CBD absorption. This study compared CBD pharmacokinetics after providing CBD oil as sublingual drops and within orally ingested gelatin capsules, at a dose relevant to consumer products. Materials and Methods: Eight males completed three conditions in a participant-blinded, randomized crossover design. Participants received the following combinations of placebo and CBD-containing (69 mg/mL) hemp oil in capsules and as sublingual drops: placebo capsules/placebo drops (Placebo), CBD capsules/placebo drops (CBD-Caps), and placebo capsules/CBD drops (CBD-Drops). Blood samples, blood pressure, and subjective scales were obtained/completed hourly for 6 h and at 24 h. Discussion: Plasma CBD concentrations were not different between CBD-Caps and CBD-Drops (interaction effect p=0.76). Peak CBD concentration (28.0±15.6 vs. 24.0±22.2 ng/mL), time of peak CBD concentration (4±1 vs. 4±2 h), and area under the concentration curve (45.3±20.3 vs. 41.8±23.3 ng/mL·6 h) were not different between conditions (p≥0.25). Cardiometabolic outcomes (plasma glucose/triacylglycerol, heart rate, blood pressure), liver function (plasma alanine aminotransferase/aspartate aminotransferase), kidney function (plasma creatinine), and subjective feelings/symptoms were not different between conditions (p≥0.07). Conclusions: Plasma CBD profiles were comparable between CBD-Caps and CBD-Drops, suggesting that there were not meaningful differences in routes of CBD absorption between conditions. This implies that CBD oil delivered sublingually is swallowed before oral mucosal CBD absorption occurs, which may have implications for research design, CBD product design, and consumer product choice.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

以舌下滴剂或明胶胶囊形式摄入的大麻二酚油在健康男性中显示出相似的药代动力学特征。

简介：大麻二酚（CBD）是一种无毒的植物大麻素，用于临床治疗，在消费品中广泛销售。CBD产品可以设计用于舌下或口服，但尚不清楚两者是否有利于CBD的吸收。这项研究比较了以舌下滴剂形式提供CBD油和在口服明胶胶囊中以与消费品相关的剂量提供CBD油后的CBD药代动力学。材料和方法：八名男性在一项参与者盲法随机交叉设计中完成了三种条件。参与者接受了以下安慰剂和含CBD的组合（69 mg/mL）大麻油胶囊和舌下滴剂：安慰剂胶囊/安慰剂滴剂（安慰剂）、CBD胶囊/安慰剂滴剂（CBD Caps）和安慰剂胶囊/CBD滴剂（CBD滴剂）。每小时采集/完成6次血样、血压和主观量表 h和24 h.讨论：CBD帽和CBD滴之间的血浆CBD浓度没有差异（相互作用效应p=0.76）。峰值CBD浓度（28.0±15.6 vs.24.0±22.2 ng/mL），CBD浓度峰值时间（4±1 vs.4±2 h）和浓度曲线下面积（45.3±20.3 vs.41.8±23.3 ng/mL·6 h）不同条件下没有差异（p≥0.25）。心脏代谢结果（血浆葡萄糖/三酰甘油、心率、血压）、肝功能（血浆丙氨酸氨基转移酶/天冬氨酸氨基转移酶）、肾功能（血浆肌酐），主观感觉/症状在不同条件下没有差异（p≥0.07）。结论：CBD Caps和CBD Drops之间的血浆CBD图谱具有可比性，表明不同条件下CBD吸收途径没有显著差异。这意味着舌下输送的CBD油在口腔粘膜吸收CBD之前被吞咽，这可能对研究设计、CBD产品设计和消费者产品选择产生影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊